Cargando…
Immune Responses against SARS-CoV-2—Questions and Experiences
Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533170/ https://www.ncbi.nlm.nih.gov/pubmed/34680460 http://dx.doi.org/10.3390/biomedicines9101342 |
_version_ | 1784587247072313344 |
---|---|
author | Mangge, Harald Kneihsl, Markus Schnedl, Wolfgang Sendlhofer, Gerald Curcio, Francesco Domenis, Rossana |
author_facet | Mangge, Harald Kneihsl, Markus Schnedl, Wolfgang Sendlhofer, Gerald Curcio, Francesco Domenis, Rossana |
author_sort | Mangge, Harald |
collection | PubMed |
description | Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else (“sterilizing” immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others (“protective” immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune–vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories. |
format | Online Article Text |
id | pubmed-8533170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85331702021-10-23 Immune Responses against SARS-CoV-2—Questions and Experiences Mangge, Harald Kneihsl, Markus Schnedl, Wolfgang Sendlhofer, Gerald Curcio, Francesco Domenis, Rossana Biomedicines Review Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else (“sterilizing” immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others (“protective” immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune–vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories. MDPI 2021-09-28 /pmc/articles/PMC8533170/ /pubmed/34680460 http://dx.doi.org/10.3390/biomedicines9101342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mangge, Harald Kneihsl, Markus Schnedl, Wolfgang Sendlhofer, Gerald Curcio, Francesco Domenis, Rossana Immune Responses against SARS-CoV-2—Questions and Experiences |
title | Immune Responses against SARS-CoV-2—Questions and Experiences |
title_full | Immune Responses against SARS-CoV-2—Questions and Experiences |
title_fullStr | Immune Responses against SARS-CoV-2—Questions and Experiences |
title_full_unstemmed | Immune Responses against SARS-CoV-2—Questions and Experiences |
title_short | Immune Responses against SARS-CoV-2—Questions and Experiences |
title_sort | immune responses against sars-cov-2—questions and experiences |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533170/ https://www.ncbi.nlm.nih.gov/pubmed/34680460 http://dx.doi.org/10.3390/biomedicines9101342 |
work_keys_str_mv | AT manggeharald immuneresponsesagainstsarscov2questionsandexperiences AT kneihslmarkus immuneresponsesagainstsarscov2questionsandexperiences AT schnedlwolfgang immuneresponsesagainstsarscov2questionsandexperiences AT sendlhofergerald immuneresponsesagainstsarscov2questionsandexperiences AT curciofrancesco immuneresponsesagainstsarscov2questionsandexperiences AT domenisrossana immuneresponsesagainstsarscov2questionsandexperiences |